Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL3611677 | 0.90 | SLC10A2 (0.49) | SLC10A2 | |
| SCHEMBL5762558 | 0.86 | SLC10A2 (0.53) | SLC10A2 | |
| Ammonia Solution, Strong SCHEMBL1183723 | 0.86 | SLC10A2 (0.52) | SLC10A2 | |
| SCHEMBL4790922 | 0.86 | SLC10A2 (0.44) | SLC10A2 | |
| SCHEMBL1362226 | 0.84 | SLC10A2 (0.72) | SLC10A2 | |
| SCHEMBL932324 | 0.84 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL931560 | 0.84 | SLC10A2 (0.58) | SLC10A2 | |
| Ammonia Solution, Strong SCHEMBL5497725 | 0.82 | SLC10A2 (0.52) | SLC10A2 | |
| SCHEMBL1362231 | 0.81 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL3611683 | 0.76 | SLC10A2 (0.34) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226943-B2 | Benzothiepine ileal bile acid transport inhibitors | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | claimed |
| EP-1427718-B1 | BENZOTHIEPINE ILEAL BILE ACID TRANSPORT INHIBOTORS | ASTRAZENECA AB (SE) | 2006-11-15 | — | — | EP | claimed |
| US-20050043393-A1 | Benzothiepine ileal bile acid transport inhibitors | ASTRAZENECA AB | 2005-02-24 | — | — | US | claimed |
| US-7906502-B2 | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-7893048-B2 | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-7871998-B2 | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7863265-B2 | 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia | ASTRAZENECA AB (SE) | 2011-01-04 | — | — | US | disclosed |
| US-7842684-B2 | 2-azetidinone derivatives such as N-({4-[(2R,3R)-3-{[(2R)-2-(4-fluorophenyl)-2-hydroxyethyl]thio}-1-(4-{3-[(methylsulfonyl)amino]prop-1-yn-1-yl}phenyl)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-cyclohexyl-D-alanine, used for the treatment of hyperlipemia | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| US-20100216759-A1 | Novel 2-Azetidinone Derivatives And Their Use As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemia | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20100168075-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | disclosed |
| US-20100152156-A1 | 2-Azetidinone Derivatives For The Treatment Of Hyperlipidaemic Diseases | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| EP-1894564-A2 | Use of an ibat inhibitor for the treatment of prophylaxis of constipation | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1877067-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070142304-A1 | Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-7226943-B2 | Benzothiepine ileal bile acid transport inhibitors | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | disclosed |
| WO-2006116499-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | MICROBIA, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060199797-A1 | Use of an ibat inhibitor for the treatment of prophylaxis of constipation | ALBIREO AB (SE) | 2006-09-07 | — | — | US | disclosed |
| US-20060083790-A1 | Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea | ALBIREO AB (SE) | 2006-04-20 | — | — | US | disclosed |
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
| US-20050043393-A1 | Benzothiepine ileal bile acid transport inhibitors | ASTRAZENECA AB | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142304-A1 | Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity | CYP46A1, CYP51A1, NPC1L1 | SLC10A2 139/4885 |
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | CYP46A1, CYP27A1, CYP7A1 | SLC10A2 149/4885 |
| US-20060083790-A1 | Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea | SLC10A2, SI, SLC6A1 | SLC10A2 1/4885 |
| US-20060199797-A1 | Use of an ibat inhibitor for the treatment of prophylaxis of constipation | SLC10A2, GABRQ, SLC6A1 | SLC10A2 1/4885 |
| US-20100216759-A1 | Novel 2-Azetidinone Derivatives And Their Use As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemia | CYP46A1, NPC1L1, LIPA | SLC10A2 77/4885 |
| US-20050043393-A1 | Benzothiepine ileal bile acid transport inhibitors | SLC10A2, SLC10A1, ABCB11 | SLC10A2 1/4885 |
| US-20100168075-A1 | Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions | CYP46A1, NPC1L1, NPC1 | SLC10A2 60/4885 |
| US-20100152156-A1 | 2-Azetidinone Derivatives For The Treatment Of Hyperlipidaemic Diseases | NPC1L1, CYP46A1, PCSK9 | SLC10A2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.